|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, Ncam1 was highly expressed in leukemic progenitor cells in a murine leukemia model, and genetic depletion of <i>Ncam1</i> prolonged disease latency and significantly reduced leukemia-initiating cells upon serial transplantation.
|
30814062 |
2019 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Described for the first time in 1994 as CD4+ cutaneous lymphoma with high expression of CD56, BPDCN has been known previously with various names such as blastic natural killer (NK) leukemia/lymphoma, agranular CD4+ CD56+ hematodermic neoplasm, and agranular CD4+ NK cell leukemia.
|
29237977 |
2018 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD56 expression in acute myeloid leukemia (AML) has been associated with extramedullary leukemia and multidrug resistance, but its clinical and prognostic significance has not been clearly identified.
|
16986129 |
2007 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our study suggests that KIT activating mutations in AML with t(8; 21) are associated with diminished CD 19 and positive CD56 expression on leukemic blasts and, thus, can be phenotypically distinguished from AML1-ETO leukemias without KIT mutations.
|
17875504 |
2007 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
The combined overexpression of RUNX1 and NCAM during stress hematopoiesis in children with DS might be a key factor in the development of overt leukemia and/or in the growth advantage of the malignant GATA1s clone in ML- DS.
|
17043020 |
2006 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The combined overexpression of RUNX1 and NCAM during stress hematopoiesis in children with DS might be a key factor in the development of overt leukemia and/or in the growth advantage of the malignant GATA1s clone in ML- DS.
|
17043020 |
2006 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Differential gene-expression profiling in the leukemia cell lines derived from indolent and aggressive phases of CD56+ T-cell large granular lymphocyte leukemia.
|
14712486 |
2004 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Standard MFC techniques were used to determine CD56 expression on the leukemia blasts cells.
|
12008081 |
2002 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD56 expression was analyzed in leukemic cells from 94 adults with primary AML in Taiwan and was correlated with clinical and hematologic features, cytogenetics, and immunophenotypes of the leukemia.
|
12189644 |
2002 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report 4 cases of lymphomas/leukemias with the unusual CD56/CD4 phenotype.
|
11488062 |
2001 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
They showed two unusual features, including immunoreactivity for CD56 and a short-lived but rapidly progressive myelodysplastic phase preceding the appearance of frank leukemia.
|
11408070 |
2001 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Agranular CD4+CD56+ blastic natural killer leukemia/lymphoma.
|
11401089 |
2001 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is an unusual case of CD56(+) aggressive lymphoma/leukemia characterized by the clonal expansion of two phenotypically different cell populations, variably balanced during the course of the disease.
|
10800166 |
2000 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Because CD56 expression has been associated with both extramedullary leukemia and multidrug resistance, we sought to correlate CD56 expression with treatment outcome in AML with t(8;21).
|
9269784 |
1997 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we analysed the cytogenetic findings of seven patients with CD56-positive putative NK cell lymphoma/leukaemia.
|
9326190 |
1997 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In three patients with leukaemia in a blastic phase (BP) it was only possible to obtain one culture enriched in CD56+CD3- cells (81%).
|
8639431 |
1996 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
As previously reported, CD56+ leukemias occurred in a frequency of about 20% of ANLL cases showing clinical and immunophenotypical heterogeneity.
|
1372833 |
1992 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data showed no evidence of direct involvement of these genes in this leukemia but enabled a partial genetic map of this important region of the human genome to be constructed: 11cen--NCAM--CD3([G, D], E)--parallel--(ETS1, THY1)--11qter.
|
3248386 |
1988 |